Cytek Biosciences, Inc. (CTKB) Balance Sheet

The reduction in total assets appears to be driven by a significant drawdown in cash reserves, which have fallen by over 50% from their 2024 peak. This trend suggests that the company is increasingly reliant on its existing balance sheet to fund ongoing operations rather than organic asset growth.

While the current ratio remains robust at 4.69, the absolute decline in cash reserves warrants close monitoring by investors. The company's ability to sustain its current R&D and manufacturing investment levels may become constrained if the cash burn rate does not moderate in the coming quarters.

The low leverage profile provides a degree of flexibility, yet the recent increase in debt from $14.1M in 2023Q4 to $36.3M in 2026Q1 may indicate a shift toward utilizing credit facilities to bridge the gap between operational cash outflows and revenue generation. This transition should be monitored for potential impacts on future interest expenses.

The consistent erosion of retained earnings highlights the fundamental challenge of scaling the business model to reach profitability. Investors should consider whether the current equity base can support further expansion without requiring additional dilutive capital raises if the current burn rate persists.